Is adjuvant chemotherapy useful for women with luminal a breast cancer?

Journal of Clinical Oncology

Volumn 30, Issue 12, 2012, Pages 1260-1263

  Coates, Alan S ^a   Colleoni, Marco ^b   Goldhirsch, Aron ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Klinik St Anna   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CLINICAL PRACTICE; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADJUVANT CHEMOTHERAPY; ADULT; AGE; AGED; BREAST TUMOR; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FEMALE; INTERNATIONAL COOPERATION; METHODOLOGY; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SEGMENTAL MASTECTOMY; SURVIVAL;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 84862242969     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.7879     Document Type: Note

References (45)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. The National Institutes of Health Consensus Development Conference: Adjuvant Therapy for Breast Cancer-Bethesda, Maryland, USA: November 1-3, 2000-Proceedings. J Natl Cancer Inst Monogr 5-15, 2001
3. Carlson RW, Allred DC, Anderson BO, et al: Invasive breast cancer. J Natl Compr Canc Netw 9:136-222, 2011
4. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
5. Nielsen TO, Parker JS, Leung S, et al: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222-5232, 2010
6. Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5-23, 2011
7. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001 (Pubitemid 32878711)
8. Phipps AI, Buist DS, Malone KE, et al: Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 22:399-405, 2011
9. Millikan RC, Newman B, Tse CK, et al: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123-139, 2008 (Pubitemid 351538762)
10. Blows FM, Driver KE, Schmidt MK, et al: Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279, 2010
11. Nguyen PL, Taghian AG, Katz MS, et al: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378, 2008
12. Hugh J, Hanson J, Cheang MC, et al: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168-1176, 2009
13. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
14. Wo JY, Taghian AG, Nguyen PL, et al: The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys 77:188-196, 2010
15. Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes: Dealing with the diversity of breast cancer-Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747, 2011
16. Thurlimann B, Price KN, Gelber RD, et al: Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 113:137-144, 2009
17. Cardoso F, Van't Veer L, Rutgers E, et al: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 26:729-735, 2008 (Pubitemid 351264385)
18. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001 (Pubitemid 32176272)
19. van De Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002 (Pubitemid 35461656)
20. Aebi S, Sun Z, Braun D, et al: Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. Ann Oncol 22:1981-1987, 2011
21. Viale G, Regan MM, Maiorano E, et al: Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 26:1404-1410, 2008
22. Karlsson P, Sun Z, Braun D, et al: Long-term results of International Breast Cancer Study Group Trial VIII: Adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 22:2216-2226, 2011
23. Colleoni M, Cole BF, Viale G, et al: Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 28:2966-2973, 2010
24. Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750, 2009
25. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006 (Pubitemid 46622311)
26. Albain KS, Barlow WE, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
27. Conforti R, Boulet T, Tomasic G, et al: Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: A biomarker study from two randomized trials. Ann Oncol 18:1477-1483, 2007 (Pubitemid 47365479)
28. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
29. Andre F, Broglio K, Roche H, et al: Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with nodepositive breast cancer: Results from a pooled analysis. J Clin Oncol 26:2636-2643, 2008
30. Penault-Llorca F, André F, Sagan C, et al: Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2809-2815, 2009
31. Pagani O, O'Neill A, Castiglione M, et al: Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632-640, 1998
32. Calleoni M, Gelber S, Goldhirsch A, et al: Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 24:1332-1341, 2006 (Pubitemid 46621995)
33. Swain SM, Jeong JH, Wolmark N: Amenorrhea from breast cancer therapy: Not a matter of dose. N Engl J Med 363:2268-2270, 2010
34. Swain SM, Jeong JH, Geyer CE Jr, et al: Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-2065, 2010
35. Colleoni M, Sun Z, Martinelli G, et al: The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: Results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 20:1344-1351, 2009
36. Rodenhuis S, Bontenbal M, Beex LV, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349:7-16, 2003 (Pubitemid 36765098)
37. Goldhirsch A, Gelber RD, Yothers G, et al: Adjuvant therapy for very young women with breast cancer: Need for tailored treatments. J Natl Cancer Inst Monogr 30:44-51, 2001
38. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007 (Pubitemid 46698581)
39. Colleoni M, Bagnardi V, Rotmensz N, et al: Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 116:359-369, 2009
40. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010
41. Paridaens RJ, Gelber S, Cole BF, et al: Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 123:303-310, 2010
42. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
43. Puhalla S, Brufsky A, Davidson N: Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast 18:S122-S130, 2009 (suppl 3)
44. Hayes DF: Targeting adjuvant chemotherapy: A good idea that needs to be proven! J Clin Oncol 30:1264-1267, 2012
45. Early Breast Cancer Trialists' Collaborative Group: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet [epub ahead of print on December 5, 2011]